A Pittsburgh philanthropist and retired Mellon exec thinks so. In 1988, Jeffrey L. Morby left American Express to join the management team tapped to rescue the nearly bankrupt Mellon Bank. After helping turn Mellon around, he retired at 59, but Morby has hardly been wiling away the time.
On behalf of the Board of Directors and the Research Consortium, we want to thank all the donors, researchers and academic institutional partners supporting Cure Alzheimer’s Fund research for your help in making 2011 such a successful science year. Guided by leading scientists in the field, Cure Alzheimer’s Fund-supported research continues to make breakthrough progress toward our goal of eradicating Alzheimer’s disease.
Our focus on funding high-quality, innovative work is fueling progress in Alzheimer’s research
It has been an outstanding year at Cure Alzheimer’s Fund(CAF). Our strategy of using a business and venture approach for funding research is working. We’ve been recognized in The Wall Street Journal, Time magazine and AARP, featured on NPR and CNN.com and invited to exclusive conferences at the White House, TEDMED and the Milken Institute.
Currently, for every dollar spent on Alzheimer’s care, only a penny is spent working toward a cure. This is a bad equation for a disease that is estimated will cost well more than $100 billion in care (Medicare and Medicaid alone) in 2009.
Currently, for every dollar spent on Alzheimer's care, only a penny is spent working toward a cure. This is a bad equation for a disease that is estimated to cost more than $100 billion in care (Medicare and Medicaid alone) in 2009.
We set out three years ago to jumpstart progress toward a cure for Alzheimer’s disease and we are succeeding.
The Alzheimer’s Genome Project™ (AGP), targeting the full set of Alzheimer’s genetic risk factors, identified seventy new genes, a tremendous result and truly breakthrough research.New genes open extensive novel scientific avenues for better understanding the disease and development of effective therapies.
Publications announcing these results have begun and findings will continue to be announced in coming months.
Other funded work, such as the AlzGene tool which allows researchers around the world to share and analyze information, is driving progress forward in unprecedented ways.
The personal and economic impact of Alzheimer’s is enormous and the path to a cure is through research.
When we first met with Dr. Rudy Tanzi to discuss Cure Alzheimer's Fund, we asked him two things:
Can you recruit a group of first-class Alzheimer’s researchers to guide us in our investment in basic research into the causes of the disease?
What is the most important first step we can take to truly make a difference?
Dr. Tanzi answered the first question by assembling the group of researchers known as the Cure Alzheimer’s Fund Research Consortium. They answered the second question thusly: find all the genes that contribute to risk for Alzheimer’s disease.
Dr. Tanzi estimated that task would take about three years and about $3 million. He was right.
First, a hearty thank you to all of you who have supported us. Your money has been put to good use. The first operating year of Cure Alzheimer’s Fund has been most gratifying for the founders, donors, researchers --- all of us committed to doing what we can to end the scourge of Alzheimer’s disease in our lifetime.